You are currently viewing a new version of our website. To view the old version click .
  • Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematology Reports, Volume 12, Issue 1

May 2020 - 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

  • Case Report
  • Open Access
1 Citations
1,307 Views
3 Pages

The Curious Case of Hemoglobin DC Disease Masquerading as Sickle Cell Anemia

  • Samina Hirani,
  • Supriya Gupta,
  • Diana Veillon,
  • Shajadi Patan,
  • Samip Master and
  • Richard Mansour

Hemoglobin D is a relatively rare disease first reported in 1951. We present the first reported case of Hemoglobin DC disease. This is a case of a Hemoglobinopathy with DC disease in a woman with a previous diagnosis of Hemoglobin SC disease. A 19-ye...

  • Case Report
  • Open Access
3 Citations
1,057 Views
4 Pages

Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression

  • Yusuke Yamashita,
  • Yoshikazu Hori,
  • Hideki Kosako,
  • Takehiro Oiwa,
  • Kenji Warigaya,
  • Toshiki Mushino,
  • Shogo Murata,
  • Masakazu Fujimoto,
  • Akinori Nishikawa and
  • Shin-ichi Murata
  • + 2 authors

Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”)....

  • Case Report
  • Open Access
4 Citations
1,045 Views
3 Pages

Successful Allogeneic Bone Marrow Transplantation Using Immunosuppressive Conditioning Regimen for a Patient with Red Blood Cell Transfusion-Dependent Pyruvate Kinase Deficiency Anemia

  • Maiko Shimomura,
  • Takehiko Doi,
  • Shiho Nishimura,
  • Yusuke Imanaka,
  • Shuhei Karakawa,
  • Satoshi Okada,
  • Hiroshi Kawaguchi and
  • Masao Kobayashi

Pyruvate kinase deficiency (PKD) is the rare glycolytic enzyme defect causing hemolytic anemia. Treatments are mainly red cell transfusion and/or splenectomy, leading to iron overload. Allogeneic bone marrow transplantation (BMT) is alternatively cur...

  • Article
  • Open Access
1 Citations
869 Views
9 Pages

Effect of Antiepileptic Drugs on Plasma Fibrinogen Level

  • Rasha Abd El Malk El-Ashry,
  • M. M. El-Ayuoty,
  • H. A. Azzam and
  • M. A. El-Naggar

Background: Childhood epilepsy is one of the most common neurological disorders in pediatrics. The prevalence of active epilepsy is 5–8 per 1000 population in developed countries and 10 per 1000 population in developing nations. Th...

  • Article
  • Open Access
2 Citations
891 Views
6 Pages

Immunoistochemical Expression of PD-1 and PD-L1 in Bone Marrow Biopsies of Patients with Acute Myeloid Leukemia

  • Francesco Romano,
  • Antonino Giulio Giannone,
  • Sergio Siragusa,
  • Rossana Porcasi and
  • Ada Maria Florena

Haematological and non-haematological malignancies are able to escape the host immune by the capacity to hijack the immune check-points [...]

  • Article
  • Open Access
3 Citations
1,027 Views
5 Pages

Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients

  • Rafiye Ciftciler,
  • Hakan Goker,
  • Yahya Buyukasik,
  • Nilgun Sayınalp,
  • Ibrahim C. Haznedaroglu,
  • Salih Aksu,
  • Osman Ozcebe and
  • Haluk Demiroglu

The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8–10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) reg...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Hematol. Rep. - ISSN 2038-8330